What Teva Pharmaceutical Industries (TEVA)'s FDA Approval of UZEDY for Bipolar I Disorder Means For Shareholders

• On October 10, 2025, Teva Pharmaceuticals and Medincell announced that the FDA approved UZEDY® as a once-monthly injectable for the maintenance treatment of bipolar I disorder in adults, following its earlier approval for adult schizophrenia in 2023.
• This approval introduces the first subcutaneous, long-acting risperidone formulation for bipolar I disorder, leveraging Medincell’s proprietary SteadyTeq™ technology, and widens Teva’s specialty pharmaceutical offering in high-need therapeutic areas.
• We'll now examine how the addition of UZEDY’s new FDA-approved indication shapes Teva’s investment outlook and future earnings potential.

We've found 17 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.

Teva Pharmaceutical Industries Investment Narrative Recap

To be a shareholder in Teva Pharmaceutical Industries, you need to believe in its ability to transition from a predominantly generics-focused business to a balanced growth model, driven by innovative specialty drugs like UZEDY. The recent FDA approval of UZEDY for bipolar I disorder expands its branded portfolio and could strengthen short-term growth prospects, but it does not materially change the main catalyst: successful execution on branded product launches. The biggest risk remains Teva’s significant debt burden, which continues to limit financial flexibility despite operational advances.

Among recent announcements, Teva’s South Korean approval for UZEDY in schizophrenia stands out as closely related to the latest U.S. news. This international progress underscores the potential for UZEDY to become a global growth contributor, reinforcing the importance of pipeline execution and regulatory success as key drivers for the company’s near-term and medium-term outlook. However, investors should also weigh how heavily Teva’s branded success now hinges on a few products as market conditions shift.

By contrast, Teva’s substantial debt load remains a key area investors should be mindful of, as ...

Read the full narrative on Teva Pharmaceutical Industries (it's free!)

Teva Pharmaceutical Industries is projected to achieve $17.8 billion in revenue and $1.5 billion in earnings by 2028. This outlook is based on an assumed annual revenue growth rate of 2.3% and a $1.66 billion increase in earnings from the current $-157.0 million level.

Uncover how Teva Pharmaceutical Industries' forecasts yield a $24.22 fair value, a 28% upside to its current price.

Exploring Other Perspectives

Fourteen different fair value estimates from the Simply Wall St Community put Teva’s worth anywhere between US$24.22 and US$58.26 per share. As Teva’s growth now depends more on branded drug execution and less on generics, these opinions reflect how investors are weighing pipeline momentum and structural risks.

Explore 14 other fair value estimates on Teva Pharmaceutical Industries - why the stock might be worth over 3x more than the current price!

Build Your Own Teva Pharmaceutical Industries Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Teva Pharmaceutical Industries research is our analysis highlighting 5 key rewards that could impact your investment decision.
• Our free Teva Pharmaceutical Industries research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Teva Pharmaceutical Industries' overall financial health at a glance.

Want Some Alternatives?

These stocks are moving-our analysis flagged them today. Act fast before the price catches up:

• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 26 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.
• These 15 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch.
• Explore 27 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com